NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With RRMM (LUMMICAR STUDY 1)

(LUMMICAR STUDY 1)

NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.

Sponsor

CARsgen Therapeutics Co., Ltd

Collaborators

Beijing Chao Yang Hospital

The First Affiliated Hospital of Soochow University

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Tianjin Medical University General Hospital

First Affiliated Hospital of Zhejiang University

Beijing Hospital

Shanghai Tongji Hospital, Tongji University School of Medicine

First Affiliated Hospital of Wenzhou Medical University

Xiangya Hospital of Central South University

Peking University People's Hospital

Qilu Hospital of Shandong University

Sun Yat-sen University

First Affiliated Hospital, Sun Yat-Sen University

---

ClinicalTrials.gov Identifier: NCT03975907

Open Label, Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Fully Human Anti-BCMA Chimeric Antibody Receptor Autologous T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

First Posted : June 5, 2019